Levothyroxine treatment and incident dementia in adults with atrial fibrillation
(2020) In Aging clinical and experimental research 32(3). p.433-439- Abstract
Objective: Levothyroxine treatment is common among older adults as is atrial fibrillation (AF), yet less is known about its potential effects on the development of dementia. Methods: The study population included all adults with diagnosed AF (n = 156,104) aged ≥ 45 years in Sweden without an earlier recorded diagnosis of dementia. Individuals with a dispensed prescription of levothyroxine on two or more occasions between July 1 2005 and December 31 2006 in Sweden were considered exposed (n = 12,978; 8.3%), and were compared to all other patients with AF without this treatment. Cox regression with hazard ratios (HRs) and 95% confidence interval (95% CI), with outcome defined as dementia of all causes between January 1, 2007 and December... (More)
Objective: Levothyroxine treatment is common among older adults as is atrial fibrillation (AF), yet less is known about its potential effects on the development of dementia. Methods: The study population included all adults with diagnosed AF (n = 156,104) aged ≥ 45 years in Sweden without an earlier recorded diagnosis of dementia. Individuals with a dispensed prescription of levothyroxine on two or more occasions between July 1 2005 and December 31 2006 in Sweden were considered exposed (n = 12,978; 8.3%), and were compared to all other patients with AF without this treatment. Cox regression with hazard ratios (HRs) and 95% confidence interval (95% CI), with outcome defined as dementia of all causes between January 1, 2007 and December 31, 2015, was used in the analysis. Adjustments were made for socio-demographic factors (age, immigration status, marital status, educational level, neighborhood socioeconomic status), co-morbidity (cardiovascular disease, obesity, diabetes, COPD, depression, anxiety and alcohol related diagnoses), and cardiovascular medications. Results: During follow-up, a total of 9054 patients with AF were diagnosed with dementia (5.8%). We found no significant association of levothyroxine treatment and incident dementia, fully adjusted HR 1.03 (95% CI 0.96–1.11), neither among men and women, nor in different age-groups or subgroups of dementia. Conclusion: We found no significant association of levothyroxine treatment and incident dementia among patients with AF, which contrasts some earlier findings.
(Less)
- author
- Wändell, Per LU ; Carlsson, Axel C. ; Li, Xinjun LU ; Sundquist, Jan LU and Sundquist, Kristina LU
- organization
- publishing date
- 2020-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer’s disease, Atrial fibrillation, Dementia, Drug treatment, Gender, Levothyroxine
- in
- Aging clinical and experimental research
- volume
- 32
- issue
- 3
- pages
- 7 pages
- publisher
- Kurtis
- external identifiers
-
- scopus:85066892460
- pmid:31119696
- ISSN
- 1594-0667
- DOI
- 10.1007/s40520-019-01217-3
- language
- English
- LU publication?
- yes
- id
- 2c75fb41-253f-4203-806d-2435de982db0
- date added to LUP
- 2019-06-24 13:56:09
- date last changed
- 2024-04-30 14:04:23
@article{2c75fb41-253f-4203-806d-2435de982db0,
abstract = {{<p>Objective: Levothyroxine treatment is common among older adults as is atrial fibrillation (AF), yet less is known about its potential effects on the development of dementia. Methods: The study population included all adults with diagnosed AF (n = 156,104) aged ≥ 45 years in Sweden without an earlier recorded diagnosis of dementia. Individuals with a dispensed prescription of levothyroxine on two or more occasions between July 1 2005 and December 31 2006 in Sweden were considered exposed (n = 12,978; 8.3%), and were compared to all other patients with AF without this treatment. Cox regression with hazard ratios (HRs) and 95% confidence interval (95% CI), with outcome defined as dementia of all causes between January 1, 2007 and December 31, 2015, was used in the analysis. Adjustments were made for socio-demographic factors (age, immigration status, marital status, educational level, neighborhood socioeconomic status), co-morbidity (cardiovascular disease, obesity, diabetes, COPD, depression, anxiety and alcohol related diagnoses), and cardiovascular medications. Results: During follow-up, a total of 9054 patients with AF were diagnosed with dementia (5.8%). We found no significant association of levothyroxine treatment and incident dementia, fully adjusted HR 1.03 (95% CI 0.96–1.11), neither among men and women, nor in different age-groups or subgroups of dementia. Conclusion: We found no significant association of levothyroxine treatment and incident dementia among patients with AF, which contrasts some earlier findings.</p>}},
author = {{Wändell, Per and Carlsson, Axel C. and Li, Xinjun and Sundquist, Jan and Sundquist, Kristina}},
issn = {{1594-0667}},
keywords = {{Alzheimer’s disease; Atrial fibrillation; Dementia; Drug treatment; Gender; Levothyroxine}},
language = {{eng}},
number = {{3}},
pages = {{433--439}},
publisher = {{Kurtis}},
series = {{Aging clinical and experimental research}},
title = {{Levothyroxine treatment and incident dementia in adults with atrial fibrillation}},
url = {{http://dx.doi.org/10.1007/s40520-019-01217-3}},
doi = {{10.1007/s40520-019-01217-3}},
volume = {{32}},
year = {{2020}},
}